日韩欧美 a级,国产又色又爽又刺激在线观看,偷偷色噜狠狠狠狠的777米奇,浮妇高潮喷白浆视频

GDC-0068

    98%

GDC-0068

源葉(MedMol)
S80002
1001264-89-6
C24H32ClN5O2
458
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
品牌 貨號(hào) 產(chǎn)品規(guī)格 價(jià)格(RMB) 庫存(上海) 北京 武漢 南京 購買數(shù)量
源葉(MedMol) S80002-1mg 98% ¥200.00元 9 - - -
源葉(MedMol) S80002-5mg 98% ¥544.00元 5 - - -
源葉(MedMol) S80002-10mg 98% ¥748.00元 6 - - -
源葉(MedMol) S80002-25mg 98% ¥1360.00元 4 - - -
源葉(MedMol) S80002-50mg 98% ¥2244.00元 預(yù)計(jì)交期:2-3天 - - -
源葉(MedMol) S80002-100mg 98% ¥4216.00元 預(yù)計(jì)交期:2-3天 - - -
產(chǎn)品介紹 參考文獻(xiàn) 質(zhì)檢證書(COA) 摩爾濃度計(jì)算器 相關(guān)產(chǎn)品

產(chǎn)品介紹

Ipatasertib (GDC-0068) is a highly selective and ATP-competitive pan-Akt inhibitor with IC50s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively.
產(chǎn)品描述: Ipatasertib (GDC-0068) is a highly selective and ATP-competitive pan-Akt inhibitor with IC50s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively.
靶點(diǎn): Akt1:5 nM (IC50);Akt2:18 nM (IC50);Akt3:8 nM (IC50);PKA:3100 nM (IC50);Akt
體內(nèi)研究: Ipatasertib (GDC-0068) is typically efficacious in xenograft models in which Akt is activated because of genetic alterations including PTEN loss, PIK3CA mutations/amplifications, or HER2 overexpression. In these models, tumor growth delay, stasis, or regression is achieved at or below 100 mg/kg daily oral dose, which is the maximum dose tested in immunocompromised mice that is well tolerated. When tested in vivo, daily dosing of Ipatasertib (GDC-0068) in combination with RP-56976 induces tumor regression and stasis in the PC-3 and MCF7-neo/HER2 xenograft models, at doses where each single agent is ineffective or only causes modest tumor growth delay. Similarly, increased TGI is observed in the OVCAR3 ovarian cancer xenograft model when Ipatasertib (GDC-0068) is combined with NSC 241240. The combination of Ipatasertib (GDC-0068) with RP-56976 or NSC 241240 is tolerated with less than 5% body weight loss when compared with treatment with each chemotherapeutic agent alone
參考文獻(xiàn): 1. Blake JF, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012 Sep 27;55(18):8110-27. 2. Lin J, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res. 2013 Apr 1;19(7):1760-72.
溶解性: DMSO  :  220  mg/mL  (480.35  mM;  Need  ultrasonic)    H2O  :  3.57  mg/mL  (7.79  mM;  ultrasonic  and  warming  and  heat  to  60°C)
保存條件: -20℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 2.183 ml 10.917 ml 21.834 ml
5 mM 0.437 ml 2.183 ml 4.367 ml
10 mM 0.218 ml 1.092 ml 2.183 ml
50 mM 0.044 ml 0.218 ml 0.437 ml
注意: 部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。

參考文獻(xiàn)

質(zhì)檢證書(COA)

如何獲取質(zhì)檢證書(COA)?
請(qǐng)輸入貨號(hào)和一個(gè)與之匹配的批號(hào)。
例如:
批號(hào):JS298415 貨號(hào):S20001-25g
在貨品標(biāo)簽上如何找到貨號(hào)和批號(hào)?

摩爾濃度計(jì)算器

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×

相關(guān)產(chǎn)品